ANAB - CIK 0001370053
The table below shows ANAPTYSBIO, INC's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $238.20M | $123.08M | $35.97M | $71.31M | $495.73M | $250.46M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $350.25M |
| $431.88M |
| $406.83M |
| $447.20M |
| $553.88M |
| $396.56M |
| Property, plant & equipment | $1.37M | $1.85M | $2.10M | $2.09M | $2.28M | $1.78M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $364.39M | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M |
| Accounts payable | $3.87M | $4.00M | $4.70M | $2.78M | $1.74M | $4.22M |
| Total current liabilities | $38.63M | $45.43M | $37.44M | $26.05M | $16.10M | $19.82M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$772.56M | -$759.33M | -$614.10M | -$450.48M | -$321.75M | -$263.96M |
| Total equity | $37.21M | $70.87M | $88.10M | $262.10M | $356.43M | $396.73M |